글로벌 과호산구증후군 시장 – 2029년까지의 산업 동향 및 예측

과호산구증후군 시장 분석 및 규모

글로벌 과호산구증 시장은 예측 기간 동안 상당한 성장을 보일 것으로 예상됩니다. 높은 진단율과 의료 시설의 개선은 시장 성장을 주도하는 영향 요인 중 일부입니다. 개발도상국의 의료 인프라 확장과 제네릭 의약품의 가용성은 예측 기간 동안 과호산구증 시장을 주도하는 주요 요인 중 일부입니다. COVID-19도 시장 성장에 큰 영향을 미쳤습니다.

Data Bridge Market Research는 2022-2029년 예측 기간 동안 글로벌 과호산구증 시장의 성장률을 분석합니다. 글로벌 과호산구증 시장의 예상 CAGR은 언급된 예측 기간 동안 약 9%인 경향이 있습니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 시장 세그먼트, 지리적 범위, 시장 참여자 및 시장 시나리오와 같은 시장 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함되어 있습니다.

시장 정의

과호산구 증후군은 호산구의 비정상적으로 높은 농도로 인해 장기 손상, 주로 피부, 폐, 심장 및 위장관 손상을 특징으로 하는 혈액학적 장애입니다. 호산구는 면역 체계를 유지하는 데 도움이 되는 혈액의 필수 구성 요소인 백혈구의 일종입니다. 호산구 수가 많으면 고통스러운 감염성 질환의 스펙트럼을 나타낼 수 있습니다.  

과호산구증가증후군 시장 범위 및 세분화

Global Hypereosinophilic Syndrome Market Dynamics

Drivers

• Increasing Cases of Cancer

Increasing incidence of cancer is boosting the growth of the market. As per the reports of the American Cancers Society in 2018, around 1,735,350 new cases of cancer will be diagnosed, and approximately 609,640 cancer deaths are estimated in the U.S. in 2018. This boosts the market growth.

• Rising Demand for Oral Drugs

Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.

Opportunities

• Rise in Autoimmune Disorders

As per the records of the America Autoimmune Related Disease Association (AARDA), around 50 million Americans suffered from autoimmune disorders back in 2017, and their incidence is still on the rise. Hence, it boosts the market growth.

• Increasing Demand for Retail Pharmacies

The rise in the number of narcotic drugs delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.

 Restraints/Challenges

• Lack of Awareness about the infection

The lack of awareness about this syndrome could curb the growth of the global hypereosinophilic syndrome market over a forecast period. Not much awareness about the syndrome leads to improper treatment thus restraining the market growth.

• High Cost

The huge expenditure associated with these agents surely hamper the market growth.

This global hypereosinophilic syndrome market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global hypereosinophilic syndrome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Hypereosinophilic Syndrome Market Scope

The global hypereosinophilic syndrome market is segmented on the basis of treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Biological Therapy
• Corticosteroid
• Chemotherapy
• Others

Route of Administration

• Oral
• Injectable

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Hypereosinophilic Syndrome Market Regional Analysis/Insights

The global hypereosinophilic syndrome market is analysed and market size insights and trends are provided by treatment, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global hypereosinophilic syndrome market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing a positive growth for hypereosinophilic syndrome market throughout the forecasted period due to leading leaders in research and development.

North America dominates the market due to the high demand for disease-specific treatment, rise in adoption of newer technologies, presence of refined healthcare expenditure, increased patient awareness level, and high prevalence of bleeding disorders.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Hypereosinophilic Syndrome Market Share Analysis

글로벌 과호산구증 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우위가 있습니다. 제공된 위의 데이터 포인트는 글로벌 과호산구증 시장과 관련된 회사의 초점에만 관련이 있습니다.

글로벌 과호산구증후군 시장에서 활동하는 주요 기업은 다음과 같습니다.

• 파이저 주식회사(미국)
• 마일런 NV(미국)
• 노바티스 AG(스위스)
• Hikma Pharmaceuticals plc (영국)
• Aurobindo Pharma(인도)
• AbbVie Inc. (아일랜드)
• 멜린타 테라퓨틱스 주식회사(미국)
• 브리스톨-마이어스 스퀴브 회사(미국)
• GSK plc. (영국)
• Bayer AG(독일)
• 루팡(인도)
• 미션파마칼 컴퍼니(미국)
• Bausch Health Companies Inc. (캐나다)
• Sun Pharmaceutical Industries Ltd. (인도)
• Aurobindo Pharma(인도)
• 루팡(인도)
• Fresenius Kabi AG(독일)
• Amneal Pharmaceuticals LLC. (미국)

SKU-53966